Celldex director granted options on 26,000 shares

Celldex Therapeutics director James J. Marino received a grant of stock options as part of his equity compensation.

Rhea-AI Filing Summary

Celldex Therapeutics director James J. Marino received a grant of stock options as part of his equity compensation. He was awarded non-qualified options covering 26,000 shares of Common Stock, with an exercise price of $34.09 per share. The options were granted under Celldex’s 2021 Omnibus Equity Incentive Plan, carry no upfront cost to Marino, and are exercisable beginning on June 25, 2027. These options are scheduled to expire on June 25, 2036 if not exercised. After this grant, Marino holds options on 26,000 shares according to this filing.

Insider Trade Summary

Grant/Award: 26,000 shares

Grant/Award 1 txn

Insider MARINO JAMES J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Non-Qualified Stock Option (right to buy)	26,000	$0.00	$0.00

Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 26,000 contracts (Direct)

Footnotes (1)

1. F1. Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

Key Figures

Options granted: 26,000 options Underlying shares: 26,000 shares Exercise price: $34.09 per share +5 more

8 metrics

Options granted 26,000 options Non-qualified stock option grant to director James J. Marino

Underlying shares 26,000 shares Common Stock underlying the option grant

Exercise price $34.09 per share Strike price for the non-qualified stock options

Exercisable starting June 25, 2027 Date options become exercisable

Expiration date June 25, 2036 Date the options expire if unexercised

Post-grant option holdings 26,000 options Total options held after this transaction per filing

Transaction code A Grant, award, or other acquisition of derivative security

Transaction date June 25, 2026 Date of option grant

Key Terms

Non-Qualified Stock Option, 2021 Omnibus Equity Incentive Plan, Common Stock

3 terms

Non-Qualified Stock Option financial

"Non-Qualified Stock Option (right to buy)"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

2021 Omnibus Equity Incentive Plan financial

"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Celldex Therapeutics (CLDX) director James J. Marino report on this Form 4?

James J. Marino reported receiving a grant of non-qualified stock options for 26,000 Celldex shares. The award is part of his equity compensation and does not represent an open-market purchase or sale of common stock.

How many Celldex (CLDX) shares are covered by Marino’s new stock options?

The grant covers options on 26,000 shares of Celldex common stock. These options give Marino the right to buy that number of shares at a fixed exercise price if he chooses to exercise them before expiration.

What is the exercise price of James Marino’s Celldex (CLDX) stock options?

The options have an exercise price of $34.09 per share. This means Marino can buy Celldex common stock at $34.09 per share when he exercises the options, regardless of the market price at that time.

When can Marino begin exercising his Celldex (CLDX) stock options from this grant?

The options are exercisable beginning June 25, 2027. After that date, Marino may choose to exercise some or all of the 26,000 options any time before they expire, subject to the plan’s terms.

When do James Marino’s newly granted Celldex (CLDX) stock options expire?

The options expire on June 25, 2036 if they are not exercised. After that expiration date, Marino would no longer have the right to purchase Celldex shares at the fixed $34.09 exercise price from this grant.

Under which plan were James Marino’s Celldex (CLDX) options granted?

The options were granted under Celldex Therapeutics’ 2021 Omnibus Equity Incentive Plan. This plan authorizes the company to issue stock-based awards, such as options, to directors and other eligible participants as part of their compensation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 04:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MARINO JAMES J

(Last) (First) (Middle)

C/O CELLDEX THERAPEUTICS, INC.

53 FRONTAGE ROAD, SUITE 220

(Street)

HAMPTON NEW JERSEY 08827

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Celldex Therapeutics, Inc. [ CLDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)(1)	$34.09	06/25/2026(1)		A		26,000		06/25/2027	06/25/2036	Common Stock	26,000	$0	26,000	D

Explanation of Responses:

1. Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

	/s/ Sam Martin, attorney-in-fact for James J. Marino	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)